Abstract
Conjunctival melanoma is a rare primary ocular tumor. So far, no standard treatment exists for metastatic disease. Similarly to cutaneous melanoma, up to 50% of conjunctival melanomas harbor BRAF mutations. The most common is represented by V600E. Combined therapy with BRAF and MEK inhibitors is approved for BRAF mutant cutaneous metastatic melanomas. Herein, we report a case of a 70-years old patient with a metastatic conjunctival melanoma harboring V600E BRAF mutation successfully treated with dabrafenib and trametinib.
| Original language | English |
|---|---|
| Pages (from-to) | 232 |
| Journal | Frontiers in Oncology |
| Volume | 9 |
| DOIs | |
| Publication status | Published - 2019 |
Fingerprint
Cite this
Rossi, E., Maiorano, B. A., Pagliara, M. M., Sammarco, M. G., Dosa, T., Martini, M., Rindi, G., Bria, E., Blasi, M. A., Tortora, G., & Schinzari, G. (2019). Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma. Frontiers in Oncology, 9, 232. https://doi.org/10.3389/fonc.2019.00232